

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2389751/publications.pdf>

Version: 2024-02-01

36  
papers

1,460  
citations

394421

19  
h-index

377865

34  
g-index

37  
all docs

37  
docs citations

37  
times ranked

3041  
citing authors

#	ARTICLE	IF	CITATIONS
1	Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis. <i>Hepatology</i> , 2011, 54, 1707-1717.	7.3	291
2	Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition. <i>Autophagy</i> , 2017, 13, 1767-1781.	9.1	152
3	A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition. <i>Hepatology</i> , 2012, 55, 1776-1786.	7.3	127
4	Genomic Predictors for Recurrence Patterns of Hepatocellular Carcinoma: Model Derivation and Validation. <i>PLoS Medicine</i> , 2014, 11, e1001770.	8.4	117
5	Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. <i>Hepatology</i> , 2016, 63, 159-172.	7.3	115
6	Hepatocellular Carcinoma with Irregular Rim-Like Arterial Phase Hyperenhancement: More Aggressive Pathologic Features. <i>Liver Cancer</i> , 2019, 8, 24-40.	7.7	66
7	Keratin 19 Expression in Hepatocellular Carcinoma Is Regulated by Fibroblast-Derived HGF via a MET-ERK1/2-AP1 and SP1 Axis. <i>Cancer Research</i> , 2018, 78, 1619-1631.	0.9	60
8	Poor outcome of hepatocellular carcinoma with stemness marker under hypoxia: resistance to transarterial chemoembolization. <i>Modern Pathology</i> , 2016, 29, 1038-1049.	5.5	52
9	Peroxiredoxin II Is Essential for Maintaining Stemness by Redox Regulation in Liver Cancer Cells. <i>Stem Cells</i> , 2016, 34, 1188-1197.	3.2	40
10	Increased Expression of CCN2, Epithelial Membrane Antigen, and Fibroblast Activation Protein in Hepatocellular Carcinoma with Fibrous Stroma Showing Aggressive Behavior. <i>PLoS ONE</i> , 2014, 9, e105094.	2.5	36
11	Gross type of hepatocellular carcinoma reflects the tumor hypoxia, fibrosis, and stemness-related marker expression. <i>Hepatology International</i> , 2020, 14, 239-248.	4.2	34
12	Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma. <i>Liver International</i> , 2018, 38, 113-124.	3.9	33
13	Dynamics of Genomic, Epigenomic, and Transcriptomic Aberrations during Stepwise Hepatocarcinogenesis. <i>Cancer Research</i> , 2019, 79, 5500-5512.	0.9	33
14	Tumor stroma with senescence-associated secretory phenotype in steatohepatitic hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0171922.	2.5	32
15	Increased Expression of Circulating Cancer Stem Cell Markers During the Perioperative Period Predicts Early Recurrence After Curative Resection of Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 1444-1452.	1.5	29
16	Tumour epithelial and stromal characteristics of hepatocellular carcinomas with abundant fibrous stroma: fibrolamellar versus scirrhous hepatocellular carcinoma. <i>Histopathology</i> , 2017, 71, 217-226.	2.9	29
17	Human PinX1 Mediates TRF1 Accumulation in Nucleolus and Enhances TRF1 Binding to Telomeres. <i>Journal of Molecular Biology</i> , 2009, 388, 928-940.	4.2	22
18	Increased expression of stemness markers and altered tumor stroma in hepatocellular carcinoma under TACE-induced hypoxia: A biopsy and resection matched study. <i>Oncotarget</i> , 2017, 8, 99359-99371.	1.8	20

#	ARTICLE	IF	CITATIONS
19	Lung and lymph node metastases from hepatocellular carcinoma: Comparison of pathological aspects. <i>Liver International</i> , 2022, 42, 199-209.	3.9	19
20	Increased Expression of the Matrix-Modifying Enzyme Lysyl Oxidase-Like 2 in Aggressive Hepatocellular Carcinoma with Poor Prognosis. <i>Gut and Liver</i> , 2019, 13, 83-92.	2.9	19
21	PinX1, a Telomere Repeat-binding Factor 1 (TRF1)-interacting Protein, Maintains Telomere Integrity by Modulating TRF1 Homeostasis, the Process in Which Human Telomerase Reverse Transcriptase (hTERT) Plays Dual Roles. <i>Journal of Biological Chemistry</i> , 2014, 289, 6886-6898.	3.4	17
22	Clinicopathological characteristics of intrahepatic cholangiocarcinoma according to gross morphologic type: cholangiolocellular differentiation traits and inflammation- and proliferation-phenotypes. <i>Hpb</i> , 2020, 22, 864-873.	0.3	17
23	Rare Incidence of <i>ROS1</i> Rearrangement in Cholangiocarcinoma. <i>Cancer Research and Treatment</i> , 2017, 49, 185-192.	3.0	16
24	Suppression of PROX1-mediated TERT expression in hepatitis B viral hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2018, 143, 3155-3168.	5.1	13
25	Molecular and radiopathologic spectrum between HCC and intrahepatic cholangiocarcinoma. <i>Hepatology</i> , 2023, 77, 92-108.	7.3	13
26	Progressive Enrichment of Stemness Features and Tumor Stromal Alterations in Multistep Hepatocarcinogenesis. <i>PLoS ONE</i> , 2017, 12, e0170465.	2.5	12
27	Noninvasive surrogates are poor predictors of liver fibrosis in patients with Fontan circulation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, 1176-1185.e3.	0.8	10
28	The Clinicopathological Significance of YAP/TAZ Expression in Hepatocellular Carcinoma with Relation to Hypoxia and Stemness. <i>Pathology and Oncology Research</i> , 2021, 27, 604600.	1.9	8
29	Clinical and survival outcomes after hepatectomy in patients with non-alcoholic fatty liver and hepatitis B-related hepatocellular carcinoma. <i>Hpb</i> , 2021, 23, 1113-1122.	0.3	6
30	YAP inactivation in estrogen receptor alpha-positive hepatocellular carcinoma with less aggressive behavior. <i>Experimental and Molecular Medicine</i> , 2021, 53, 1055-1067.	7.7	6
31	Genetic, Clinicopathological, and Radiological Features of Intrahepatic Cholangiocarcinoma with Ductal Plate Malformation Pattern. <i>Gut and Liver</i> , 2022, 16, 613-624.	2.9	6
32	Circulating Cancer Stem Cells Expressing EpCAM/CD90 in Hepatocellular Carcinoma: A Pilot Study for Predicting Tumor Recurrence after Living Donor Liver Transplantation. <i>Gut and Liver</i> , 2022, 16, 443-455.	2.9	5
33	Pathological predictive factors for late recurrence of hepatocellular carcinoma in chronic liver disease. <i>Liver International</i> , 2021, 41, 1662-1674.	3.9	3
34	Combined tumor epithelial and stromal histopathology with keratin 81 expression predicts prognosis for pancreatic ductal adenocarcinoma. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, , .	2.6	2
35	A study to identify incidence of <i>ROS1</i> rearrangement in lung adenocarcinoma, cholangiocarcinoma and glioblastoma multiforme.. <i>Journal of Clinical Oncology</i> , 2015, 33, e22203-e22203.	1.6	0
36	The dual role of transforming growth factor-beta signatures in human B viral multistep hepatocarcinogenesis: early and late responsive genes. <i>Journal of Liver Cancer</i> , 0, , .	1.1	0